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Recently, great interest has focused on the phenomenon of aspirin resistance, which may be
defined as clinical or laboratory resistance. Monitoring the antiplatelet effect appears to be
relevant in the presence of clinical implications, but no data are available on the possible clinical
implications of the failure of aspirin to inhibit tests of platelet function in the setting of acute
coronary syndromes. This study evaluated the role of aspirin resistance in the occurrence of
1-year major adverse coronary events (MACEs) in patients with acute myocardial infarction
(AMI) who have undergone percutaneous coronary intervention (PCI). We prospectively
evaluated 146 patients (115 men and 31 women; median age 65 years, range 30 to 84) with AMI
who underwent primary PCI. Exclusion criteria were the use of glycoprotein IIb/IIIa inhibitors,
hematocrit <30%, and a platelet count <100,000/mm3. Platelet function analyzer-100 closure
times by collagen-epinephrine were used for measuring platelet function in venous blood
samples obtained 12 to 15 hours after revascularization. Patients were considered aspirin
resistant in the presence of a collagen-epinephrine closure time of <203 seconds. After 1-year
follow-up, MACEs were recorded in 44 of 146 patients (30.1%). A significantly higher percent-
age of patients with MACEs had aspirin resistance (39.1% vs 23.2%, p<0.05). A Kaplan-Meier
survival curve showed that the overall risk of MACEs was significantly higher among patients
with aspirin resistance (p  0.02). A Cox regression analysis that adjusted for age, gender,
traditional cardiovascular risk factors, systolic left ventricular function, number of stenosed
coronary arteries, and previous AMI, PCI, or coronary artery bypass graft showed aspirin
resistance to be a significant and independent risk factor for the future MACEs (hazard ratio
2.9, 95% confidence interval 1.1 to 9.2, p <0.05). In conclusion, our data demonstrate that
aspirin resistance after PCI is a significant and independent predictor of MACEs in patients
with AMI undergoing primary PCI. © 2006 Elsevier Inc. All rights reserved. (Am J Cardiol
2006;98:1156–1159)
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espirin is the cornerstone of antiplatelet therapy in cardio-
ascular medicine and has been reported to decrease the risk
f cardiovascular events by about 25% in a broad category
f patients with arterial vascular disease.1 In recent years,
uch attention has been focused on the phenomenon of
spirin resistance, which may be defined as a failure of
herapy to prevent clinical events (i.e., clinical aspirin re-
istance) or as a failure of aspirin to inhibit platelet function
n “in vitro” tests (i.e., laboratory aspirin resistance).2 Sev-
ral studies have documented the prevalence of laboratory
spirin resistance in different groups of patients with car-
iovascular disease,3,4 but the question not yet definitively
nswered is whether aspirin resistance is associated with an
ncreased risk of cardiovascular events. Some studies in the
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oi:10.1016/j.amjcard.2006.05.041iterature have investigated the clinical implications of as-
irin resistance in chronic coronary artery disease5–8 and
tent thrombosis,9,10 but no data exist for patients with acute
yocardial infarction (AMI) who have undergone primary
ercutaneous coronary intervention (PCI). Thus, we evalu-
ted whether aspirin resistance affects the occurrence of
ajor adverse cardiac events (MACEs) in patients with
MI who have undergone primary PCI by measuring plate-
et function with a point-of-care assay (PFA-100).11
ethods and Results
he study population included 147 patients (31 women;
edian age 65 years, range 30 to 84) who were admitted to
he Coronary Care Unit of the Azienda Ospedaliero, Uni-
ersitaria Careggi, University of Florence (Florence, Italy)
ith a diagnosis of AMI. AMI was diagnosed based on an
ncrease in creatine kinase-MB isoenzyme 2 times the
pper normal limits (3.6 ng/ml) and/or increased cardiac
roponin I levels (0.15 ng/ml) with 1 of the following:
cute onset of prolonged (20 minutes) typical ischemic
hest pain; ST-segment elevation 1 mm in 2 contiguous
lectrocardiographic leads or ST-depression 0.5 mm 0.08
econd after the J point in2 contiguous leads, or a T-wave
www.AJConline.org
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1157Coronary Artery Disease/Aspirin Resistance and Major Adverse Cardiac Eventsnversion 1 mm in leads with predominant R waves. All
atients underwent coronary angiography according to the
udkins technique and primary PCI with stent implantation
bare metal stents in 82, drug-eluting stents in 76). Exclu-
ion criteria included a history of bleeding diathesis, a
latelet count100,000/mm3, hematocrit30%, creatinine
evel 4.0 mg/dl, and glycoprotein IIb/IIIa inhibitor use.
Informed written consent was obtained from all patients,
nd the study was approved by the local ethical review
oard. With regard to follow-up, data were obtained by a
tructured telephone interview at 1 year and a clinical eval-
ation in case of clinical recurrences and/or new PCI. Clin-
cal end points were a composite of MACEs, including
ardiac death (defined as death from AMI, pump failure,
udden cardiac death, or death due to arrhythmias), new
MI, and target lesion revascularization for symptomatic
estenosis. Restenosis was defined as a diameter stenosis
50% in patients needing target vessel revascularization
ecause of symptoms or signs of ischemia. A diagnosis of
ardiac death, new AMI, and target lesion revascularization
or symptomatic restenosis, which determined the allocation
f patients into groups with or without MACEs, was made
y 2 cardiologists (CG and SV) who were unaware of the
latelet function test results. Blood samples anticoagulated
ith 0.129 mol/L of sodium citrate (ratio 9:1) were taken
rom each patient 12 to 15 hours after PCI. The PFA-100
evice (Dade-Behring, Marburg, Germany) was used to
easure platelet function at high shear conditions on whole
itrated blood. The method determines the time to occlusion
f an aperture in a membrane coated with collagen and
pinephrine (closure time/epinephrine). von Willebrand fac-
or levels were measured with an enzyme-linked fluorescent
ssay (Biomerieux, Lyon, France). Two hundred control
amples from healthy subjects who took no drugs for 10
ays were run to determine normal reference laboratory
alues (closure time/epinephrine median 142 seconds, range
9 to 207). Aspirin resistance was defined by a closure
ime/epinephrine of 203 seconds (95th percentile of con-
rol distribution).
Statistical analysis was performed with SPSS 11.5 for
indows (SPSS, Inc., Chicago, Illinois). Values are pre-
ented as geometric mean (95% confidence interval) or
edian and range. Nonparametric Mann-Whitney test for
npaired data was used for comparisons between single
roups. For analysis of MACEs in relation to time of the
vent, Cox regression analysis was used, with age (contin-
ous variable), gender, traditional cardiovascular risk fac-
ors (hypertension, smoking habitus, diabetes mellitus, dys-
ipidemia, and family history of coronary artery disease),
jection fraction, number of stenosed coronary arteries, and
spirin resistance as the independent variables. In addition,
e analyzed the interval from hospital admission to occur-
ence of MACEs (uncensored observations) or to telephone
nterview (censored observation) to estimate the probability
f MACEs as a function of time, according to the Kaplan-
eier method. The probability of MACEs was compared
cross groups with the log-rank test. All odds ratios are
resented with their 95% confidence intervals. All p values
re 2-tailed, with values 0.05 considered statistically sig-
ificant.All patients received a loading dose of 300 mg of tlopidogrel orally before PCI and 500 mg of acetylsali-
ylic acid intravenously, followed by 75 mg/day of clo-
idogrel and 100 mg/day of aspirin. Unfractionated hep-
rin, 70 IU/kg, was used during the procedure as an
nticoagulant.
MACEs were recorded in 44 of 146 patients (30.1%): 15
ardiovascular deaths, 12 target lesion revascularizations,
nd 17 recurrent AMIs. Clinical characteristics of patients
ccording to occurrence of MACEs are presented in
able 1. Diabetes, number of stenosed vessels, and ejection
raction were the only parameters that significantly differed
ccording to the occurrence of MACEs.
Aspirin resistance was found in 41 of 146 patients
28.0%). Long-term use of aspirin was associated with a
ignificantly lower prevalence of aspirin resistance. Thirty-
hree of 46 patients were on aspirin before AMI; 21 of 33
63.6%) had aspirin resistance compared with 20 of 113
atients (17.6%) with no previous use of aspirin
p 0.0001). None of the clinical characteristics inves-
1
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igure 1. Kaplan-Meier event-free rates according to response to aspirin
herapy.
able 1
linical characteristics of patients according to occurrence of major
dverse cardiac events
ariable MACEs p Value
Yes No
(n  44) (n  103)
ge (yrs) 64.5 12.2 63.4 10.5 0.2
en 31 (70.4%) 84 (82.3%) 0.08
mokers 15 (34%) 44 (43.1%) 0.3
ypertension 26 (59%) 71 (69.6%) 0.3
iabetes mellitus 22 (50%) 27 (26.4%) 0.05
yslipidemia 15 (34%) 55 (53.9%) 0.1
jection fraction (%) 44 12.7 48.9 9.3 0.05
revious MI, PCI, coronary
artery bypass graft
5 (11.3%) 15 (14.7%) 0.4
o. of stenosed coronary
vessels
1.7  0.8 1.4 0.7 0.05igated, i.e., age, gender, hypertension, smoking, diabe-
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1158 The American Journal of Cardiology (www.AJConline.org)es, and dyslipidemia, was associated with a significantly
igher prevalence of aspirin resistance.
Eighteen of 41 aspirin-resistant patients (43.9%) had a
ubsequent MACE compared with 26 of 105 aspirin-
esponder patients (24.8%, p 0.05). In particular, 6 of
5 patients (40%) with cardiovascular death, 8 of 12
66%) with target lesion revascularization, and 4 of 17
23.5%) with recurrent AMI were aspirin resistant. The
aplan-Meier survival curve showed that the overall risk
f MACEs was significantly higher among patients with
spirin resistance (p  0.02; Figure 1). In contrast, a
ignificantly higher percentage of patients with MACEs
ad aspirin resistance (39.1% vs 23.2%, p 0.05). No
ignificant difference in von Willebrand factor levels
etween patients with or without a subsequent MACE
as documented (228%, range 38% to 500%, vs 221.2%,
ange 38% to 480%, p  NS).
A Cox regression analysis that was adjusted for age,
ender, diabetes, number of stenosed coronary arteries, and
jection fraction (i.e., the parameters with a significantly
igher prevalence in patients with MACEs vs patients with-
ut MACEs) showed aspirin resistance to be a significant
nd independent risk factor for the future occurrence of
ACEs (hazard ratio 2.9, 95% confidence interval 1.1 to
.2, p 0.05).
iscussion
n the present study, we provide the first evidence that
spirin resistance, measured after primary PCI in patients
ith AMI, is an independent predictor of MACEs after
-year follow-up.
We found a high prevalence of aspirin resistance in our
atients. High platelet activation in patients with AMI with
espect to stable coronary artery disease may be associated
ith a high prevalence of aspirin resistance. A high aden-
sine diphosphate level in patients with AMI was hypoth-
sized to contribute to increased platelet activity and weaker
ffect of aspirin.12 The increased prevalence of aspirin re-
istance in AMI could be explained by an increased activity
f important feedback systems such as adenosine diphos-
hate and thromboxane13 and by an increase in von Wille-
rand factor released from endothelial cells under high
hear stress.14
The association of cardiovascular events with aspirin
esistance has been previously documented in chronic cor-
nary artery disease5–8 and in patients with stent thrombo-
is,9,10 whereas no data are available, to the best of our
nowledge, on patients with AMI. In 488 patients with
hronic cardiovascular disease who were treated with aspi-
in, Eikelboom et al7 documented for the first time that high
evels of 11-dehydrothromboxane B2, the stable metabolite
f thromboxane A2, are associated with an increased risk of
I or cardiovascular death. This result was confirmed in
26 patients with stable cardiovascular disease in whom
spirin resistance, diagnosed using platelet aggregation
ests, was associated with a threefold increase in the risk of
ubsequent MACEs.6 Further, aspirin resistance in patients
ho underwent elective PCI was associated with a high
ncidence of myonecrosis after PCI and with an impaired
oronary flow reserve after revascularization.5,8 Two retro-pective studies on a limited number of patients found that
hose with previous stent thrombosis had an impaired re-
ponse to antiplatelet therapy and an increased shear-in-
uced platelet aggregation.9,10 No retrospective and pro-
pective study evaluated the risk of subsequent events
ssociated with aspirin resistance in acute coronary syn-
romes.
In our group of AMI patients who underwent primary
evascularization, we evaluated platelet function in a blood
ample obtained after primary PCI, so that our results would
ppear to be easily reproducible in a “real-world” setting,
.e., in patients admitted to a catheterization laboratory for
rgent PCI. A point to be discussed is that angioplasty per
e is an important prothrombotic stimulus because disrup-
ion of the atheromatous plaque causes prolonged exposure
o subendothelial tissue factor, collagen fibronectin, and von
illebrand factor.15,16 Therefore, in our patients, platelet
yperaggregability may have resulted from the thrombotic
rocess in the culprit vessel and platelet activation related to
he revascularization procedure. Nevertheless, whatever the
rigger of platelets, an impaired response to aspirin therapy
eems to predict future MACEs, suggesting that it identifies
subgroup of patients at higher risk for new events. By
ssessing the ability of aspirin to inhibit platelet function at
he time of an acute event, it is possible to select patients for
hom a more intensive antiplatelet therapy might provide a
etter long-term benefit.
It should be emphazised that in our study, aspirin resis-
ance was determined by a point-of-care test.2 Currently,
latelet response to antiaggregating agents may be deter-
ined by simple and rapid methods potentially available in
he coronary care unit, differently from the Born method,
hich is a time-consuming method requiring specialized
aboratories.
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